{"id":21255,"date":"2026-06-01T21:30:03","date_gmt":"2026-06-01T21:30:03","guid":{"rendered":"https:\/\/jobuzo.com\/en\/akeso-lung-cancer-drug-trial-raises-hopes-in-us20b-market\/"},"modified":"2026-06-01T21:30:03","modified_gmt":"2026-06-01T21:30:03","slug":"akeso-lung-cancer-drug-trial-raises-hopes-in-us20b-market","status":"publish","type":"post","link":"https:\/\/jobuzo.com\/en\/akeso-lung-cancer-drug-trial-raises-hopes-in-us20b-market\/","title":{"rendered":"Akeso lung cancer drug trial raises hopes in US$20b market"},"content":{"rendered":"
\n
<\/div>\n
Akeso<\/span>, whose drug ivonescimab was hailed as biotech’s “DeepSeek moment” amid US competition last year, announced better-than-expected clinical results showing it can treat a type of lung cancer commonly found in smokers, potentially expanding its approved uses.<\/div>\n

Analysts suggest it could become a backbone therapy in the US$20 billion global non-small cell lung cancer market and have revised their target prices upwards.<\/p>\n

The drug’s phase three trial found that ivonescimab reduced the risk of death by 34 per cent, according to a filing with the Hong Kong stock exchange on Monday.<\/p>\n

\n
\n

Advertisement<\/p>\n<\/div>\n<\/div>\n

However, its Hong Kong-listed shares dropped 1.86 per cent to HK$115.9 apiece, bucking the market rally as the Hang Seng Index gained about 0.86 per cent on Monday.<\/p>\n

In terms of the median overall survival rate – where half of the patients in a control group are still alive – those on ivonescimab lived 27.9 months. This was nearly four months longer than the 23.7 months for patients who were prescribed global oncology developer BeOne<\/span>’s tislelizumab, which generated US$737 million in global sales in 2025, up 18.6 per cent year on year.<\/div>\n
\n
\n

Advertisement<\/p>\n<\/div>\n<\/div>\n

Nearly two-thirds of the patients – 64.7 per cent – were still alive two years after taking ivonescimab, compared with less than half, or 48.6 per cent, in the control group.<\/p>\n<\/div>\n

News :<\/span><div>12 weeks' jail for school IT support technician who took upskirt videos of teachers<\/div><\/span><\/a><\/div>

Akeso lung cancer drug trial raises hopes in US$20b market<\/sub><\/p>\n","protected":false},"excerpt":{"rendered":"

Akeso, whose drug ivonescimab was hailed as biotech’s “DeepSeek moment” amid US competition last year, announced better-than-expected clinical results showing it can treat a type of lung cancer commonly found in smokers, potentially expanding its approved uses. Analysts suggest it could become a backbone therapy in the US$20 billion global non-small cell lung cancer market…<\/p>\n

Read More “Akeso lung cancer drug trial raises hopes in US$20b market”<\/span> »<\/a><\/p>\n","protected":false},"author":1,"featured_media":21256,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-21255","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/jobuzo.com\/en\/wp-json\/wp\/v2\/posts\/21255","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jobuzo.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jobuzo.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jobuzo.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/jobuzo.com\/en\/wp-json\/wp\/v2\/comments?post=21255"}],"version-history":[{"count":0,"href":"https:\/\/jobuzo.com\/en\/wp-json\/wp\/v2\/posts\/21255\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/jobuzo.com\/en\/wp-json\/wp\/v2\/media\/21256"}],"wp:attachment":[{"href":"https:\/\/jobuzo.com\/en\/wp-json\/wp\/v2\/media?parent=21255"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jobuzo.com\/en\/wp-json\/wp\/v2\/categories?post=21255"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jobuzo.com\/en\/wp-json\/wp\/v2\/tags?post=21255"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}